Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
New HTA Scheme Should Only Cover Big-Selling Products Given Big Premiums: JPMA Chief
A new cost-effectiveness assessment scheme, which will get underway on a pilot basis next April, should only cover products that were given a “substantial” rate of premiums for usefulness and post “substantial” sales, Masayo Tada, president of the Japan Pharmaceutical…
To read the full story
Related Article
- MHLW Calls for 50% Pricing Rule for First Generics, 40% Rule for 10-Plus Oral Generics
December 4, 2015
- Chuikyo Subcommittee Agrees on Scope of “Essential Drugs”; Trial Run of Innovation Premium to Continue
December 4, 2015
- Chuikyo Basically OKs 2-Tiered Re-Pricing for Huge Seller Drugs; Sovaldi Almost Certain to Face Cut
December 3, 2015
- Generic Replacement Rate Applied to Z2 Rule to Be Hiked 10%
December 3, 2015
- Revamped Sakigake Pricing Premium to Grant Maximum Premium Rate of 20%: Chuikyo Subcommittee
December 3, 2015
REGULATORY
- Japan Approves Takeda’s Orzeyful, Insmed’s Brinsupri and More Drugs
August 25, 2026
- Japan Grants Orphan Tags to Rogocekib, Gildeuretinol, and More
August 25, 2026
- Japan Extends Re-Examination Period for Uplizna
August 25, 2026
- 4 Drug Makers Seek Govt Aid to Upgrade Aging Plants: LDP Hearing
August 24, 2026
- 679 Safety Reports Logged for Regenerative Medical Products in 2H FY2025
August 21, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…